AvenCell Therapeutics Receives FDA and EMA Clearance for Phase I/II Trial of Dual-Target Allogeneic CAR-T Therapy
核心洞察
AvenCell Therapeutics (搜索) has received FDA IND clearance and EMA approval for the QUADvance Phase I/II trial of AVC-203, a CRISPR-engineered allogeneic CAR-T therapy targeting both CD19 (搜索) and CD20 (搜索) for relapsed/refractory B-cell malignancies (搜索).
AVC-203 incorporates four key innovations including dual antigen targeting, immune evasion capabilities, improved T-cell fitness from healthy donors, and switchable targeting technology for future expansion beyond CD19 (搜索)/CD20 (搜索).
The multi-site trial will evaluate safety, tolerability, efficacy, and pharmacokinetics in adults with B-cell malignancies (搜索), addressing the scalability and cost challenges of current autologous CAR-T therapies.
AvenCell Therapeutics (搜索) has achieved a significant regulatory milestone with the FDA and European Medicines Agency (EMA) clearing the company's investigational new drug (IND) application and clinical trial application (CTA), respectively, for the QUADvance study. The Phase I/II trial will evaluate AVC-203, a CRISPR-engineered allogeneic CAR-T therapy designed to target relapsed/refractory B-cell malignancies (搜索).
Novel Dual-Target Approach
AVC-203 represents a significant advancement in CAR-T cell therapy, engineered to target and eliminate cells expressing both CD19 (搜索) and CD20 (搜索) receptors, which are expressed in nearly all B-cell malignancies (搜索). This dual-targeting approach distinguishes AVC-203 from current single-target therapies and may provide broader coverage against B-cell cancers.
"We are excited to build on the early success and promising activity and safety of our ongoing clinical program of allogeneic CAR-T in AML by now advancing into B Cell Lymphoma with what we believe to be the most scientifically compelling allogeneic technology in the industry," said Andrew Schiermeier, AvenCell's President & CEO.
Four Key Technological Innovations
AVC-203 incorporates four distinct technological features designed to address current limitations in CAR-T therapy:
Dual Antigen Targeting: The therapy contains a receptor that simultaneously targets both CD19 (搜索) and CD20 (搜索) antigens, potentially providing more comprehensive tumor coverage.
Immune Evasion: CRISPR/Cas9 engineering enables donor cells to avoid both Graft-versus-Host Disease (GvHD) and rejection by the patient's immune system, addressing key safety concerns with allogeneic approaches.
Enhanced T-cell Fitness: Allogeneic manufacturing from healthy donors leverages superior T-cell fitness compared to patient-derived cells and eliminates patient-specific production requirements, enabling immediate treatment availability.
Switchable Targeting: A RevCAR receptor dimerized to the CD19 (搜索)/CD20 (搜索) CAR enables flexible targeting of additional tumor antigens through bi- or tri-specific bridging proteins, allowing future target expansion beyond the initial CD19/CD20 targets.
Addressing Market Scalability Challenges
Schiermeier emphasized the company's focus on solving fundamental scalability issues in CAR-T therapy: "To date, attempts at solving the key scalability and cost issues of autologous CAR-T therapy by engineering cells from unrelated donors have fallen short. Nevertheless, the obvious benefits of such an approach, including consistency and potency of an actual drug product - something in vivo approaches cannot provide - remain as compelling as ever."
The company aims to ensure broader patient access through "massive scaling of supply and dramatic reductions in cost of goods, with a product that is as good or better than best-in-class autologous CAR-Ts."
Trial Design and Patient Population
The Phase I/II study will be conducted at multiple sites across the United States and Europe, evaluating the safety, tolerability, efficacy, and pharmacokinetics of AVC-203 in adults with relapsed or refractory B-cell malignancies (搜索). The trial design includes a Phase Ia dose escalation study, followed by a Phase Ib dose expansion study and a Phase II pivotal trial.
Significant Disease Burden
B-cell malignancies (搜索) represent a substantial clinical need, encompassing non-Hodgkin lymphomas (搜索), multiple myeloma (搜索), and B-cell acute lymphoblastic leukemia (搜索) (B-ALL). These conditions account for the majority of blood cancers, with approximately 120,000 new cases diagnosed annually in the United States and 150,000 in Europe.
Company Background and Strategic Vision
Founded in 2021 by Blackstone Life Sciences (搜索), Cellex Cell Professionals (搜索), and Intellia Therapeutics, AvenCell incorporated the clinical-stage biopharmaceutical company GEMoaB GmbH (搜索). The company derives its name from the French word "avenir," reflecting its aim to be the future of cell therapy.
AvenCell's broader pipeline includes programs targeting acute myeloid leukemia (搜索) (AML), with an ongoing clinical program showing early success and promising activity and safety profiles. The company is also developing additional programs for other hematological malignancies, autoimmune diseases, and solid tumors.
The company's strategic approach focuses on creating truly allogeneic cells that persist as long or longer than autologous therapies while developing universal and switchable constructs that allow complete control and target redirection of T cells after patient infusion. This integration provides significant scalability potential at orders of magnitude more efficient than current approaches.